10.5061/DRYAD.BS8C4
Hirst, Theodore C.
University of Edinburgh
Vesterinen, Hanna M.
University of Edinburgh
Conlin, Samantha
University of Edinburgh
Egan, Kieren J.
University of Edinburgh
Antonic, Ana
University of Melbourne
Lawson McLean, Aaron
University of Edinburgh
Macleod, Malcolm R.
University of Edinburgh
Grant, Robin
University of Edinburgh
Brennan, Paul M.
University of Edinburgh
Sena, Emily S.
University of Melbourne
Whittle, Ian R.
University of Edinburgh
Data from: A systematic review and meta-analysis of gene therapy in animal
models of cerebral glioma: why did promise not translate to human therapy?
Dryad
dataset
2016
rodent models
Glioma
Gene therapy
systematic review
2016-01-09T00:00:00Z
2016-01-09T00:00:00Z
en
https://doi.org/10.1002/ebm2.6
450048 bytes
1
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
Background: The development of therapeutics is often characterized by
promising animal research that fails to translate into clinical efficacy;
this holds for the development of gene therapy in glioma. We tested the
hypothesis that this is because of limitations in the internal and
external validity of studies reporting the use of gene therapy in
experimental glioma. Method: We systematically identified studies testing
gene therapy in rodent glioma models by searching three online databases.
The number of animals treated and median survival were extracted and
studies graded using a quality checklist. We calculated median survival
ratios and used random effects meta-analysis to estimate efficacy. We
explored effects of study design and quality and searched for evidence of
publication bias. Results: We identified 193 publications using gene
therapy in experimental glioma, including 6,366 animals. Overall, gene
therapy improved median survival by a factor of 1.60 (95% CI 1.53–1.67).
Study quality was low and the type of gene therapy did not account for
differences in outcome. Study design characteristics accounted for a
significant proportion of between-study heterogeneity. We observed similar
findings in a data subset limited to the most common gene therapy.
Conclusion: As the dysregulation of key molecular pathways is
characteristic of gliomas, gene therapy remains a promising treatment for
glioma. Nevertheless, we have identified areas for improvement in conduct
and reporting of studies, and we provide a basis for sample size
calculations. Further work should focus on genes of interest in paradigms
recapitulating human disease. This might improve the translation of such
therapies into the clinic.
Gene therapy in experimental glioma: raw data & analysisData
extracted directly from studies included in the systematic review. Data
were entered into the CAMARADES data manager (Access database) and
analysed. Both the raw data and results have been exported to Excel file
(note there are several pages to the spreadsheet).Hirst_gene therapy_raw
data.xls